Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients

BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis. First-line multikinase inhibitors like sorafenib and lenvatinib are poorly tolerated and have low response rates. Several clinical trials have shown tolerability and efficacy of immunotherapy in this setting. Th...

Full description

Saved in:
Bibliographic Details
Published in:Fed Pract
Main Authors: Gaudel, Pramod, Mohyuddin, Ghulam Rehman, Fields-Meehan, January
Format: Artigo
Language:Inglês
Published: Frontline Medical Communications Inc. 2021
Subjects:
Features and Columns
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7953859/
https://ncbi.nlm.nih.gov/pubmed/33716486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12788/fp.0061
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items